1172
F. Hassine et al.
4.42 (t, 2H, J ¼ 5.8 Hz), 4.90–5.00 (m, 1H), 5.58–5.65 (m,
1H), 5.70–5.80 (m, 1H), 5.93–6.05 (m, 1H), 6.85 (d, 1H,
J ¼ 8.4Hz), 7.30–7.70 (m, 6H) ppm; 13C NMR (50 MHz,
acetone-d6): ꢁ ¼ 24.2, 32.6, 46.7, 46.9, 54.2 (t, JC–N ¼ 4.0 Hz),
57.5, 61.9, 65.5, 116.5, 120.4, 121.4 (q, JC–F ¼ 321 Hz), 121.6,
125.9, 129.4, 129.9, 131.1, 132.3, 132.6, 135.6, 143.0, 152.2,
167.1 ppm; MS (APCI): m=z ¼ 470.1 (Cþ).
{3-[4-Phenyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]-
quinoline-8-carbonyloxy]propyl}trimethylammonium
bistrifluoromethanesulfonamide (7aa, C29H35F6N3O6S2)
Following procedure A using benzaldehyde 5a and cyclopen-
tadiene 6a provided expected product 7aa as a solid in 70%
1
yield; mp 118–120ꢁC; H NMR (300 MHz, acetone-d6): ꢁ ¼
1.65–1.84 (m, 1H), 2.38–2.64 (m, 3H), 2.96–3.15 (m, 1H),
3.45 (s, 9H), 3.73–3.90 (m, 2H), 4.10–4.22 (m, 1H), 4.42 (t,
2H, J ¼ 5.8 Hz), 4.70–4.80 (m, 1H), 5.58–5.65 (m, 1H), 5.70–
5.80 (m, 1H), 5.93–6.05 (m, 1H), 6.85 (d, 1H, J ¼ 8.4 Hz),
7.25–7.75 (m, 7H) ppm; 13C NMR (50 MHz, acetone-d6):
ꢁ ¼ 24.2, 32.7, 46.8, 47.2, 54.2 (t, JC–N ¼ 3.9 Hz), 58.1, 61.9,
65.6, 116.4, 120.2, 121.4 (q, JC–F ¼ 321 Hz), 126.0, 127.8,
128.4, 129.4, 129.6, 131.2, 132.3, 135.6, 143.5, 152.5,
167.1ppm; MS (APCI): m=z ¼ 391.4 (Cþ).
{3-[4-(Methoxyphenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta-
[c]quinoline-8-carbonyloxy]propyl}trimethylammonium
bistrifluoromethanesulfonamide (7ea, C30H37F6N3O7S2)
Following procedure A using 4-methoxybenzaldehyde 5e and
cyclopentadiene 6a provided expected product 7ea as a yel-
1
lowish solid in 67% yield. H NMR (300MHz, acetone-d6):
ꢁ ¼ 1.60–1.78 (m, 1H), 2.32–2.54 (m, 3H), 2.93–3.14 (m, 1H),
3.38 (s, 9H), 3.64–3.74 (m, 2H), 3.85(s, 3H), 4.01–4.11 (m,
1H), 4.17 (t, 2H, J ¼ 5.8 Hz), 4.58 (s, 1H), 5.51–5.61 (m,
1H), 5.69–5.77 (m, 1H), 5.82–5.88 (m, 1H), 6.87 (d, 1H,
J ¼ 8.3Hz), 7.42 (d, 2H, J ¼ 8.5 Hz), 7.51 (d, 2H, J ¼ 8.5 Hz),
{3-[4-(Nitrophenyl)-3a, 4, 5, 9b-tetrahydro-3H-cyclopenta-
[c]quinoline-8-carbonyloxy]propyl}trimethylammonium
bistrifluoromethanesulfonamide (7ba, C29H34F6N4O8S2)
Following procedure A using 4-nitrobenzaldehyde 5b and
cyclopentadiene 6a provided expected product 7ba as a solid
7.63 (dd, 1H, J1 ¼ 1.4 Hz, J2 ¼ 8.3 Hz), 7.73 (s, 1H) ppm; 13
C
NMR (300 MHz, acetone-d6) : ꢁ ¼ 22.1, 38.3, 45.3, 45.8, 53.1
(t, JC–N ¼ 4 Hz), 55.0, 56.3, 61.7, 63.7, 114.8, 118.3, 121.2,
121.4 (q, JC–F ¼ 321 Hz), 124.5, 127.8, 128.0, 128.1, 129.6,
130.8, 132.4, 133.9, 148.9, 158.1, 165.5ppm; MS (APCI):
m=z ¼ 421.2 (Cþ).
1
in 93% yield; mp 132–134ꢁC; H NMR (300 MHz, acetone-
d6): ꢁ ¼ 1.55–1.80 (m, 1H), 2.35–2.58 (m, 3H), 3.01–3.20 (m,
1H), 3.40 (s, 9H), 3.70–3.90 (m, 2H), 4.10–4.22 (m, 1H),
4.42 (t, 2H, J ¼ 5.8 Hz), 4.90–5.00 (m, 1H), 5.58–5.65 (m,
1H), 5.70–5.80 (m, 1H), 5.93–6.05 (m, 1H), 6.90 (d, 1H,
J ¼ 8.6 Hz), 7.60–7.95 (m, 4H), 8.28 (d, 2H, J ¼ 8.6 Hz)
ppm; 13C NMR (50 MHz, acetone-d6): ꢁ ¼ 24.2, 32.5, 46.6,
46.7, 54.2 (t, JC–N ¼ 4.0 Hz), 57.7, 62.0, 65.4, 116.7, 120.1 (q,
JC–F ¼ 321 Hz), 120.7, 124.7, 126.0, 129.0, 129.4, 131.0,
132.3, 135.5, 148.5, 151.4, 151.8, 167.0 ppm; MS (APCI):
m=z ¼ 436.1 (Cþ).
{3-[6-(4-Nitrophenyl)-5,6a,7,11b-tetrahydro-6H-indeno-
[2,1-c]quinoline-2-carbonyloxy]propyl}trimethylammonium
bistrifluoromethanesulfonamide (7bb, C33H36F6N4O8S2)
Following procedure A using 4-nitrobenzaldehyde 5b and
indene 6b provided expected product 7bb as a solid in 85%
1
yield; mp 122–124ꢁC; H NMR (300MHz, acetone-d6): ꢁ ¼
2.23–2.38 (m, 1H), 2.40–2.54 (m, 2H), 3.05–3.38 (m, 2H),
3.45 (s, 9H), 3.78–3.90 (m, 2H), 4.30–4.54 (m, 2H), 4.60
(d, 1H, J ¼ 7.5Hz), 5.04–5.12 (m, 1H), 6.15–6.20 (m, 1H),
6.83 (d, 1H, J ¼ 8.3 Hz), 7.02–7.13 (m, 3H), 7.60–7.70 (m,
2H), 7.85 (d, 2H, J ¼ 9.1 Hz), 7.95–8.01 (m, 1H), 8.30 (d, 2H,
J ¼ 9.1Hz) ppm; 13C NMR (50 MHz, acetone-d6): ꢁ ¼ 24.2,
32.1, 46.7, 48.5, 54.2 (t, JC–N ¼ 3.9 Hz), 57.1, 57.2, 61.9,
65.5, 116.2, 120.2, 121.4 (q, JC–F ¼ 321 Hz), 123.3, 124.7,
126.1, 126.3, 127.8, 128.4, 129.1, 129.5, 129.8, 133.1, 143.4,
147.4, 148.6, 151.2, 151.3, 167.0ppm; MS (APCI): m=z ¼
486.6 (Cþ).
{3-[4-(Chlorophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta-
[c]quinoline-8-carbonyloxy]propyl}trimethylammonium
bistrifluoromethanesulfonamide (7ca, C29H34ClF6N3O6S2)
Following procedure A using 4-chlorobenzaldehyde 5c and
cyclopentadiene 6a provided expected product 7ca as a solid
1
in 89% yield; mp 202–204ꢁC; H NMR (300 MHz, acetone-
d6): ꢁ ¼ 1.60–1.80 (m, 1H), 2.35–2.58 (m, 3H), 3.01–3.20 (m,
1H), 3.40 (s, 9H), 3.70–3.90 (m, 2H), 4.10–4.22 (m, 1H),
4.42 (t, 2H, J ¼ 5.8 Hz), 4.90–5.00 (m, 1H), 5.58–5.65 (m,
1H), 5.70–5.80 (m, 1H), 5.93–6.05 (m, 1H), 6.85 (d, 1H,
J ¼ 8.4 Hz), 7.30–7.70 (m, 6H) ppm; 13C NMR (50 MHz,
acetone-d6): ꢁ ¼ 24.2, 32.6, 46.7, 47.0, 54.2 (t, JC–N ¼ 4.0 Hz),
57.5, 61.9, 65.5, 116.5 120.4, 121.4 (q, JC–F ¼ 321 Hz), 125.9,
129.4, 129.5, 129.6, 131.1, 132.3, 133.6, 135.6, 142.6, 152.2,
167.1ppm; MS (APCI): m=z ¼ 425.3 (Cþ).
{3-[6-(4-Bromophenyl)-5,6a,7,11b-tetrahydro-6H-indeno-
[2,1-c]quinoline-2-carbonyloxy]propyl}trimethylammonium
bistrifluoromethanesulfonamide (7db, C33H36BrF6N3O6S2)
Following procedure A using 4-bromobenzaldehyde 5d and
indene 6b provided expected product 7db as a yellow solid in
1
{3-[4-(Bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta-
[c]quinoline-8-carbonyloxy]propyl}-trimethylammonium
bistrifluoromethanesulfonamide (7da, C29H34BrF6N3O6S2)
Following procedure A using 4-bromobenzaldehyde 5d and
cyclopentadiene 6a provided expected product 7da as a solid
83% yield. H NMR (300 MHz, acetone-d6): ꢁ ¼ 2.15–2.36
(m, 2H), 2.98–3.05 (m, 2H), 3.37 (s, 9H), 3.38–3.44 (m,
2H), 4.17 (t, 2H, J ¼ 5.6 Hz), 4.34 (m, 1H), 4.73 (bl, 1H),
6.24 (d, 1H, J ¼ 8.3 Hz), 6.94 (m, 1H), 7.01–7.21 (m, 3H),
7.27 (s, 1H), 7.46–7.74 (m, 2H), 8.05 (d, 2H, J ¼ 8.3 Hz) ppm;
13C NMR (75 MHz, acetone-d6): ꢁ ¼ 22.1, 38.2, 45.1, 45.7,
1
in 90% yield; mp 122–124ꢁC; H NMR (300 MHz, acetone-
53.1 (t, JC–N ¼ 4 Hz), 54.9, 61.7, 63.8, 114.0, 121.4 (q, JC–F
¼
d6): ꢁ ¼ 1.60–1.80 (m, 1H), 2.35–2.58 (m, 3H), 3.01–3.20 (m,
321 Hz), 121.5, 123.8, 125.2, 125.8, 126.5, 127.3, 127.4, 127.6,
1H), 3.40 (s, 9H), 3.70–3.90 (m, 2H), 4.10–4.22 (m, 1H),